Trastuzumab Deruxtecan for Patients with HER2+ Breast Cancer (DESTINY-Breast12) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how trastuzumab deruxtecan (the study drug) might provide a positive benefit to people with metastatic breast cancer.

What is the Condition Being Studied?

HER2+ Breast Cancer

Who Can Participate in the Study?

Adults ages 18+ who:
- Have HER2+ metastatic breast cancer that is unable to be removed with surgery
- Have previously treated stable or progressing brain metastasis
- Have never been treated with tucatinib
- Are taking 2mg or less of daily dexamethasone
- Have had no more than 2 lines of treatment for brain metastasis
- Are not pregnant

For more information about who can be in this study, please contact the study team at 919-684-5301.

Age Group
Adults

What is Involved?

If you agree to take part in this study, you will:
- Get the study drug as an infusion (through IV) every 3 weeks
- Have physical exams and blood draws
- Have heart scans (ECG)
- Have imaging scans (MRI or CT)

Study Details

Full Title
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00108268
NCT: NCT04739761
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698